At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 201 enrolled
Drug / intervention
H-1337 0.6% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b Randomized, Double-masked, Active-controlled, Dose-response Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension
In Brief
A Phase 2 clinical trial evaluating H-1337 0.6%, H-1337 1.0%, and 2 other interventions for Glaucoma Open-Angle Primary and Ocular Hypertension. Completed, enrolled 201 participants across 9 sites.
Detailed Summary
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma Open-Angle Primary, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedJun 2023
Enrollment StartAug 2023
Primary CompletionAug 2024
TodayJul 2026
First PostedJun 22, 2023
Enrollment StartAug 28, 2023
Primary CompletionAug 29, 2024
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 3.0 years ago
Interventions
H-1337 0.6%drug
ophthalmic solution
H-1337 1.0%drug
ophthalmic solution
H-1337 Placebodrug
ophthalmic solution
Timolol 0.5%drug
ophthalmic solution